Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many

Urs Weber MD· @UrsWeberMD · X·2026-10-26 02:44· 13 小时前评分70

正文 · 机器翻译

Divarasib 在 KRAS G12C 突变型 NSCLC 的二线治疗中优于 adagrasib 和 sotorasib。这暂时确立了新的标准，但我希望这只是未来几年 KRAS 突变型 NSCLC 领域众多阳性试验中的第一个。 @KRASKickers @myESMO #ESMO26

21 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

引用@

Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: https://nej.md/4BiCvbk @myESMO

在 X 查看被引用的帖子

来源：Urs Weber MD · x.com